Donald Trump urges global leaders to stabilize oil prices amid U.S.-Iran tensions after strikes on nuclear sites. Warning of economic fallout, he stresses that high prices could empower adversaries, calling for collective action to protect energy security and consumer interests.
Global markets remain unexpectedly calm after US military strikes on Iran over the weekend. Despite anticipated volatility, timing, uncertainty, and cautious optimism have kept trading muted. Will this stability last, or is it just a temporary lull?
May saw a slight rise in existing home sales compared to April, though still lagging behind last year. Meanwhile, home prices soared to a record high, raising affordability concerns for buyers amidst tight inventory and economic uncertainty.
Geopolitical tensions between the U.S. and Iran cause market unrest, with the Dow fluctuating and the dollar gaining strength. Oil prices remain stable despite fears, but investors brace for potential disruptions. Businesses face supply chain risks as uncertainty looms.
Holcim has completed the spin-off of its North American business under its NextGen Growth 2030 strategy, aiming to unlock value and focus on high-growth markets. This move streamlines operations and targets sustainable expansion through strategic investments.
Bitcoin remains steady at key support levels, showing resilience amid global uncertainty, while oil prices for Brent and WTI drop as experts dismiss Iran’s threats to close the Strait of Hormuz as rhetorical, highlighting contrasting market dynamics.
A $25 billion ASX loss, driven by US-Iran tensions, has sparked superannuation concerns in Australia. Experts urge calm, advising investors to avoid panic and focus on long-term strategies amidst market volatility caused by geopolitical unrest.
The World Economic Forum’s 2025 Technology Pioneers are redefining innovation with solutions like smart robotics and asteroid mining. These trailblazers tackle global challenges with scalable tech, promising a sustainable and resilient future.
Novo Nordisk’s CagriSema, a next-generation obesity drug, shows remarkable weight loss results even at lower doses. Clinical trials reveal patients on reduced doses often lose more weight, hinting at personalized, effective treatment with fewer side effects.
Major U.S. health insurers like CVS and UnitedHealthcare are set to simplify the care approval process, impacting 257 million Americans. This reform aims to reduce delays in treatments through streamlined prior authorizations, promising a more patient-friendly healthcare system.
